CHEBI:119486 - efavirenz

Main ChEBI Ontology Automatic Xrefs Reactions Pathways Models
ChEBI Name efavirenz
ChEBI ID CHEBI:119486
Definition 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.
Stars This entity has been manually annotated by the ChEBI Team.
Secondary ChEBI IDs CHEBI:47396, CHEBI:4760, CHEBI:190461
Supplier Information ChemicalBook:CB7181559, eMolecules:2735350, ZINC000002020233
Download Molfile XML SDF
more structures >>
Wikipedia License
Efavirenz (EFV), sold under the brand names Sustiva among others, is an antiretroviral medication used to treat and prevent HIV/AIDS. It is generally recommended for use with other antiretrovirals. It may be used for prevention after a needlestick injury or other potential exposure. It is sold both by itself and in combination as efavirenz/emtricitabine/tenofovir. It is taken by mouth. Common side effects include rash, nausea, headache, feeling tired, and trouble sleeping. Some of the rashes may be serious such as Stevens–Johnson syndrome. Other serious side effects include depression, thoughts of suicide, liver problems, and seizures. It is not safe for use during pregnancy. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and works by blocking the function of reverse transcriptase. Efavirenz was approved for medical use in the United States in 1998, and in the European Union in 1999. It is on the World Health Organization's List of Essential Medicines. As of 2016, it is available as a generic medication.
Read full article at Wikipedia
Formula C14H9ClF3NO2
Net Charge 0
Average Mass 315.67500
Monoisotopic Mass 315.02739
InChI InChI=1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1
InChIKey XPOQHMRABVBWPR-ZDUSSCGKSA-N
SMILES FC(F)(F)[C@]1(OC(=O)Nc2ccc(Cl)cc12)C#CC1CC1
Roles Classification
Biological Role(s): HIV-1 reverse transcriptase inhibitor
An entity which inhibits the activity of HIV-1 reverse transcriptase.
antiviral drug
A substance used in the prophylaxis or therapy of virus diseases.
Application(s): antiviral drug
A substance used in the prophylaxis or therapy of virus diseases.
View more via ChEBI Ontology
ChEBI Ontology
Outgoing efavirenz (CHEBI:119486) has role antiviral drug (CHEBI:36044)
efavirenz (CHEBI:119486) has role HIV-1 reverse transcriptase inhibitor (CHEBI:53756)
efavirenz (CHEBI:119486) is a acetylenic compound (CHEBI:73474)
efavirenz (CHEBI:119486) is a benzoxazine (CHEBI:46969)
efavirenz (CHEBI:119486) is a cyclopropanes (CHEBI:51454)
efavirenz (CHEBI:119486) is a organochlorine compound (CHEBI:36683)
efavirenz (CHEBI:119486) is a organofluorine compound (CHEBI:37143)
IUPAC Name
(4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one
Synonyms Sources
(-)-6-CHLORO-4-CYCLOPROPYLETHYNYL-4-TRIFLUOROMETHYL-1,4-DIHYDRO-2H-3,1-BENZOXAZIN-2-ONE PDBeChem
(S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one ChemIDplus
(S)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one ChEMBL
6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one ChEMBL
Efavirenz KEGG COMPOUND
Manual Xrefs Databases
989 DrugCentral
C08088 KEGG COMPOUND
D00896 KEGG DRUG
DB00625 DrugBank
Efavirenz Wikipedia
EFZ PDBeChem
EP582455 Patent
HMDB0014763 HMDB
LSM-5526 LINCS
US5519021 Patent
View more database links
Registry Numbers Types Sources
154598-52-4 CAS Registry Number KEGG COMPOUND
154598-52-4 CAS Registry Number ChemIDplus
7387333 Reaxys Registry Number Reaxys
Citations
Milpied-Homsi B, Moran EM, Phillips EJ (2014)
Antiviral drug allergy.
Immunology and allergy clinics of North America 34, 645-62, ix [PubMed:25017682]
[show Abstract]
Corbett JW, Gearhart LA, Ko SS, Rodgers JD, Cordova BC, Klabe RM, Erickson-Viitanen SK (2000)
Novel 2,2-dioxide-4,4-disubstituted-1,3-H-2,1,3-benzothiadiazines as non-nucleoside reverse transcriptase inhibitors.
Bioorganic & medicinal chemistry letters 10, 193-195 (Source: ChEMBL) [PubMed:10673109]
[show Abstract]
Patel M, McHugh RJ, Cordova BC, Klabe RM, Erickson-Viitanen S, Trainor GL, Ko SS (1999)
Synthesis and evaluation of benzoxazinones as HIV-1 reverse transcriptase inhibitors. Analogs of Efavirenz (SUSTIVA).
Bioorganic & medicinal chemistry letters 9, 3221-3224 (Source: ChEMBL) [PubMed:10576692]
[show Abstract]
Last Modified
22 February 2017